$CROX

Crocs (CROX) Q3 2026 Earnings Call Transcript

Crocs (CROX) reported Q3 2026 revenue growth of 5%, with Crocs brand up 4% and HEYDUDE up 6%. The company raised full-year revenue guidance to up approximately 3%. Crocs saw strong international growth, with direct-to-consumer channels up 24%. Adjusted operating margins expanded to 22.3%, and the company repurchased $250 million in shares. Crocs highlighted success in clog innovation and sandal category expansion, while HEYDUDE returned to growth led by wholesale revenues.

Original reporting
Published Oct 29, 2026, 6:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 6:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Crocs (CROX) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$CROXBullishHigh
01

Why it matters

The raised guidance suggests stronger demand across international markets and may drive short-term buying pressure.

02

Market read

Guidance raise is a fresh, material development for CROX, offering a clear trading catalyst.

03

What to watch

Potential supply chain constraints or higher input costs could offset revenue growth.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

CROX provided its Q3 2026 earnings call transcript, highlighting revenue growth and an upgraded full-year guidance.

Company-level read

Ticker impact

$CROXBullishHigh confidence
Context

Q3 2026 earnings call disclosed raised full-year 2026 revenue guidance to approximately 3% growth.

Expected impact

likely upward pressure as market prices in higher revenue outlook

Evidence & confidence

Higher guidance signals stronger demand and improves earnings outlook, prompting buying interest.

Market effects

Footwear and apparel sector may see modest uplift from CROX guidance beat.

U.S. consumer discretionary sentiment could improve.

Limited to CROX and its peers; no broad market impact.

Counterpoint

If guidance is already priced in, the stock may face limited upside.

Key entities

  • Crocs, Inc.

    U.S.-listed footwear manufacturer.

Related articles

$CROXMed

UBS raises Crocs stock price target to $145 on strong results

UBS raised its price target on Crocs (CROX) to $145 from $120, citing strong Q3 results and raised guidance. The stock has surged 26% in a week. UBS noted macro uncertainty but sees balanced risk. Crocs reported adjusted earnings of $3.69 per share and revenue of $1.04B, exceeding expectations. Goldman Sachs also raised its target to $128 but maintained a Sell rating.

$CROXMed

Goldman Sachs raises Crocs stock price target on growth outlook

Goldman Sachs raised its price target on Crocs (CROX) to $128 from $95, citing stronger growth, improved profitability, and a positive outlook. The stock has surged 75.7% year-to-date. Crocs reported stronger-than-expected Q3 results, with adjusted earnings of $3.69 per share and revenue of $1.04 billion, raising its full-year outlook. The HEYDUDE brand showed positive performance after two years of negative results.

$CROXHighAI 9/10

"I thought ugly shoes were a thing of the past"... Crocs shares stage stunning turnaround after plunging 30%

Crocs shares surged 25.54% to $150.26 after strong Q3 results and an upgraded full-year outlook. Adjusted EPS of $3.69 beat estimates, and revenue reached $1.04 billion. HEYDUDE, a subsidiary, saw a 6.1% revenue increase. CEO Andrew Rees cited growth across brands and regions. Last year, shares plunged 30% due to weak guidance and market trends.